Catheter Precision shares surge 39.42% premarket after acquiring Flyte and Ponderosa to expand operating platform.

Catheter Precision surged 39.42% in premarket trading following a series of strategic announcements, including the acquisition of 80.02% of Flyte and 100% of Ponderosa from Creatd for $11.55 million, funded via cash, a 0% note, and preferred stock. The company also launched a multi-tranche private placement of Series C preferred stock, securing an initial $1.85 million with options for up to $35.56 million in additional funding. These moves, coupled with resale registration rights for investors and a placement agent agreement with Dawson James Securities, aim to restructure legacy operations, simplify the balance sheet, and expand the operating platform. The aggressive capital-raising and acquisition strategy signaled strong growth potential, aligning with the sharp premarket rally as investors reacted positively to the expanded operational and financial flexibility.